RxDoctor Payments Data

Karen Russell, MD

Hematology & Oncology · Tallahassee, FLNPI 1265492375

Payments from drug & device makers

$700,660in general payments, 2019–2025

Across 149 payments — averaging $4702.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$290K
  • Astrazeneca UK Limited$182K
  • Pfizer$75K
  • Regeneron$50K
  • E.r. Squibb & Sons, L.L.C.$45K
  • Genmab U.S., Inc.$20K
  • plus $40K from 22 others
$4,216in research payments, 2019–2025

Across 3 payments — averaging $1405.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

What the payments were for

  • Food & beverage$60094%
  • Education$376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700,660 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$39,909
Medicare patients
109
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AlecensaAlectinib Hcl25$404,318
CalquenceAcalabrutinib Maleate19$289,271
TabrectaCapmatinib Hydrochloride12$265,541
TagrissoOsimertinib Mesylate12$188,247
XtandiEnzalutamide11$158,467
LonsurfTrifluridine/Tipiracil Hcl26$132,098
EliquisApixaban55$46,843
XareltoRivaroxaban13$8,630
Anastrozole221$7,407
Exemestane21$5,497
Ondansetron Hcl30$1,521
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$1,337
Letrozole47$1,159
Tamoxifen Citrate22$969
Morphine Sulfate ErMorphine Sulfate29$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$13,901$477,51731 claims
Genentech USA, Inc.Alecensa$11$404,31825 claims
NovartisTabrecta$14$265,54112 claims
Taiho Oncology, Inc.Lonsurf$32$132,09826 claims
PfizerEliquis$74,604$46,84355 claims
Johnson & JohnsonXarelto$40$8,63013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →